Back to Search
Start Over
<scp>R‐MACLO‐IVAM</scp> regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma ‐ Long term follow up results
- Source :
- American Journal of Hematology. 96:680-689
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- We present long-term combined results of two clinical trials implementing R-MACLO-IVAM induction followed by thalidomide or rituximab maintenance in 44 patients with untreated mantle cell lymphoma (MCL). The first 22 patients (UM-MCL1 ClinicalTrials.gov identifier NCT00450801) received maintenance with thalidomide (200 mg daily until relapse/intolerable toxicity) and a subsequent cohort of 22 patients (UM-MCL2 ClinicalTrials.gov identifier NCT00878254) received rituximab (375 mg/m2 IV weekly × 4, repeated every 6 months for 3 years). Considering all 44 patients, 41 (93.2%) achieved complete response (CR), two (4.5%) partial response (PR), and one (2.3%) was not evaluated for response. With a median follow up of 7.2 years (range < 1 month to 16 years), the 5-year progression-free survival (PFS) was 55.6% (95% CI: 38.9%-69.4%) and median PFS 7.9 years (95% CI: 3.7-11 years). The 5-year OS was 83.3% (95% CI: 68.1%-91.7%) and median OS was not reached. Patients with blastic variant (n = 6) had a 5-year PFS and OS of 20.8% and 60%, respectively. Myelosuppression was the most common adverse event during immunochemotherapy. Long-term treatment-related mortality was 6.8%. Note, R-MACLO-IVAM followed by maintenance therapy is an effective regimen to induce long-term remission in MCL without need for consolidation with ASCT.
- Subjects :
- Adult
Male
medicine.medical_specialty
Adolescent
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell
Gastroenterology
Disease-Free Survival
Maintenance Chemotherapy
Young Adult
Maintenance therapy
Median follow-up
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Ifosfamide
Prospective Studies
Adverse effect
Cyclophosphamide
Aged
Etoposide
Aged, 80 and over
Not evaluated
business.industry
Remission Induction
Cytarabine
Hematology
Middle Aged
medicine.disease
Progression-Free Survival
Thalidomide
Regimen
Methotrexate
Doxorubicin
Vincristine
Female
Mantle cell lymphoma
Rituximab
business
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 10968652 and 03618609
- Volume :
- 96
- Database :
- OpenAIRE
- Journal :
- American Journal of Hematology
- Accession number :
- edsair.doi.dedup.....28842de66cb8f7eb10c5c9d47b58ec1a